Financials data is unavailable for this security.
View more
Year on year Mayinglong Pharmaceutical Group Co Ltd 's revenues fell -11.20% from 3.53bn to 3.14bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 479.00m to 443.25m, a -7.46% decrease.
| Gross margin | 43.86% |
|---|---|
| Net profit margin | 14.07% |
| Operating margin | 16.89% |
| Return on assets | 9.35% |
|---|---|
| Return on equity | 12.73% |
| Return on investment | 11.58% |
More ▼
Cash flow in CNYView more
In 2023, Mayinglong Pharmaceutical Group Co Ltd increased its cash reserves by 20.50%, or 473.43m. The company earned 604.07m from its operations for a Cash Flow Margin of 19.26%. In addition the company generated 448.27m cash from investing, though they paid out 579.16m more in financing than they received.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.94 |
|---|---|
| Tangible book value per share | 8.49 |
More ▼
Balance sheet in CNYView more
| Current ratio | 4.37 |
|---|---|
| Quick ratio | 4.06 |
| Total debt/total equity | 0.108 |
|---|---|
| Total debt/total capital | 0.0946 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 14.29% while earnings per share excluding extraordinary items fell by -7.46%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 1.48% |
|---|---|
| Div growth rate (5 year) | 21.67% |
| Payout ratio (TTM) | 40.94% |
| EPS growth(5 years) | 20.26 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -3.00 |
More ▼
